Longboard pharmaceuticals announces positive topline data from a phase 1 clinical study evaluating central nervous system pharmacokinetics and pharmacodynamics of lp352 in healthy volunteers

La jolla, calif.--( business wire )--longboard pharmaceuticals, inc. (nasdaq: lbph), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive topline results from a phase 1 clinical study evaluating the central nervous system (cns) pharmacokinetics (pk) and pharmacodynamics (pd) of lp352, an oral, centrally acting 5-ht2c superagonist, in healthy volunteers.
LBPH Ratings Summary
LBPH Quant Ranking